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Summary. Background: Prothrombin time (PT) and the inter-
national normalized ratio (INR) are still routinely measured in
patients with liver cirrhosis to assess their bleeding risk despite
the lack of correlationwith the two. Thrombin generation (TG)
assays are global assays of coagulation that are showing
promise in assessing bleeding and thrombosis risks. Aim: To
study the relationship between the INR and TG proﬁles in
cirrhosis-induced coagulopathy. Methods: Seventy-three pa-
tients with cirrhosis were studied. All TG parameters were
compared with those from a normal control group. Contact
activation was prevented using corn trypsin inhibitor. TG was
also assayed in the presence of Protac. The endogenous
thrombinpotential (ETP) ratiowas derivedbydividing theETP
with Protac by the ETP without Protac. Results: The INR
(mean 1.7) did not correlate with the ETP and the velocity of
TG (P > 0.05). There was no diﬀerence between the lag time
andETPof the two groups (P > 0.05). The velocity of TGwas
increased in cirrhosis (67.95 ± 34.8 vs. 45.05 ±
25.9 nM min)1; P = 0.016) especially in patients with INRs
between 1.21 and 2.0. Both the ETP with Protac and the ETP
ratio were increased in cirrhosis (mean 1074 ± 461.4 vs.
818 ± 357.9 nM min, P = 0.004 and 0.80 ± 0.21 vs.
0.44 ± 0.15, P £ 0.0001, respectively). Conclusion: Despite a
raised INR, TG parameters are consistent with a hypercoag-
ulable proﬁle in cirrhosis-related coagulopathy. This conﬁrms
that the PT or INR should not be used to assess bleeding risk in
these patients, and other parameters, such as TG, need to be
explored as clinical markers of coagulopathy.
Keywords: hypercoagulable, INR, liver coagulopathy, protein
C, thrombin generation.
Introduction
Since its inception by Armand Quick [1], prothrombin time
(PT) has been noted to be prolonged in patients with liver
disorders. For the past 70 years physicians worldwide have
been using this test [or its derivative, the international
normalized ratio (INR)] to assess the bleeding risk of patients
with liver disorders. The value of this test in predicting
bleeding in these patients has been questioned as no associ-
ation has been found between bleeding outcomes and PT or
INR values [2,3]. Despite this, guidelines still advocate the use
of blood products to correct the INR prior to invasive
procedures [4] and a recent multidisciplinary symposium on
the subject showed that a signiﬁcant number of physicians still
concur with this practice [5]. This practice not only can delay
these procedures, but also exposes patients to transfusion-
related complications.
Thrombin generation (TG) assays are global tests of
coagulation that measure the dynamics of thrombin pro-
duction using small amounts of tissue factor as a trigger in
order to achieve a full interplay of all coagulation factors.
Thrombin is one of the most crucial coagulation enzymes in
the coagulation cascade. It cleaves the soluble ﬁbrinogen to
the clot forming ﬁbrin. In view of this, these assays could be
superior in assessing bleeding risk when compared with the
traditional coagulation tests such as the PT and activated
partial thromboplastin time, which are completely unphys-
iological. Thrombin generation tests have already been
shown to be useful in identifying patients at an increased
risk of thrombosis [6–8] and those with bleeding tendencies
[9]. Speciﬁcally in liver disorders, Tripodi et al. [10] reported
that patients with cirrhosis had normal thrombin generation
in the presence of thrombomodulin. This publication
highlighted the limitations of the PT, as this test is only
sensitive to variations of coagulation factors (F)I, II, V,
VII and X, most of which are usually reduced in cirrhosis
but not to other factors such as FVIII which is increased,
and antithrombin (AT) and protein C (PC) which are
reduced.
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The aim of the present study was to check the utility of a
thrombin generation assay, the calibrated automated thromb-
ogram (CAT), in patients with cirrhosis and especially those
with coagulopathy as judged by a high INR. We wanted to
verify the ﬁndings from the above publication [10] which might
have been inﬂuenced by contact activation, a phenomenon that
results in a spurious increase in thrombin production as a result
of the activation of FXII, or by bias owing to some patients
having a normal PT. We also postulated that even if the
endogenous thrombin potential (ETP), which measures the
amount of thrombin produced in a given time, was normal,
there could be defects in other stages of the thrombin
production loop as recently observed in patientswith sepsis [11].
Subjects and methods
Blood samples from 73 unselected adult patients with cirrhosis
were studied as part of service development with a view to
introducing thrombin generation into routine clinical practice,
as approved by our local research ethics committee and
National Research Ethics Service guidelines. The diagnosis of
cirrhosis was based on clinical, laboratory and ultrasound
evidence. The patients were not using medications known to
affect blood coagulation, and were not known to have
hemostatic disorders other than liver disease. Severity of
cirrhosis was estimated according to model for end-stage liver
disease (MELD) classiﬁcation [12]. Thirty-eight healthy sub-
jects were also recruited after providing written informed
consent. These individuals were not taking any medications,
including oral contraception, which could have affected their
coagulation, and were not known to suffer from bleeding or
thrombotic disorders.
Unmodified thrombin generation
Blood was drawn from an antecubital vein with minimal stasis
and collected in Sarstedt Monovette blood collection tubes
(Nuembrecht, Germany) containing 0.106 M sodium citrate
(ﬁnal dilution 1:10) and 20 lg mL)1 corn trypsin inhibitor
(CTI) (Cambridge BioSciences, Peterborough, UK) to inhibit
contact factor activation. Platelet-poor plasma (PPP) was
prepared by double centrifugation at 2000 · g for 12 min at
4 C and then a further centrifugation step at 13 000 · g for
2 min in order to eliminate platelet fragments. Samples were
stored in aliquots at )45 C until tested. Thrombin generation
was assessed using the CAT method as published by Hemker
et al. [13]. Both the patient group and the control groups CTI
samples were tested at 1 pM TF. The TG parameters lag time
(LT), time to peak thrombin (ttPeak), peak thrombin (peak),
endogenous thrombin potential (ETP) and start tail time (STT)
were generated by dedicated software version 3.0.0.29 (Throm-
binoscopeTM B.V., Maastricht, the Netherlands). STT corre-
sponds to the time from the start of the reaction to when the
TG curve touches zero at the end of the reaction.We calculated
the maximum velocity of thrombin generation by dividing the
peak thrombin by the difference between the ttPeak and the
LT. The rate of thrombin inhibition was derived from the
formula
Peak thrombin (nM)
STT - ttPeak (min)
The Protac-modified TG assay
A sample of blood was taken in standard Vacutainer (Becton
Dickinson, Plymouth, UK) tubes containing 0.109 M buffered
trisodium citrate for the Protac TG studies. Protac (Pen-
tapharm, Basel, Switzerland) is a snake venom extract that
activates protein C (PC). This assay was used as previously
described [14]. The concentration of Protac used was
0.3 U mL)1 and tests were carried out at 5 pM TF. Of note
is that this assay has been validated in patients with defects in
the protein C anticoagulant pathway and has been shown to be
sensitive to deﬁciencies of PC, PS and other prothrombotic
states such as factor (F)V Leiden [14–16]. When evaluating this
assay, we had demonstrated that this does not require contact
inactivation. This was done by testing the same patients blood
with and without CTI. No variations were noted in the TG
parameters in these two groups [14]. As the third centrifugation
step (as outlined above) can be cumbersome, we tested whether
there were any differences between double and triple centrifu-
gation of plasma samples when tested at 5 pM TF. No
differences were observed (data not shown). So for this assay
which was devised to test speciﬁcally the impact of the protein
C pathway, we utilized standard double centrifugation at
2000 · g for 12 min. The patient and normal group samples
were processed in exactly the same way. The ETP ratio was
derived by dividing the ETP with Protac by the ETP without
Protac.
All the TF trigger reagents were obtained from Thrombi-
noscopeTM B.V. and contain a 4 lM L)1 ﬁnal concentration of
phospholipids. Next, 80 lL of plasma are pipetted in a 96-well
plate (Immulon 2HB, U bottom plate; Thermo Lab Systems,
Franklin, MA, USA) to which 20 lL of trigger is added.
The reaction is initiated after automated dispensing of 20 lL of
substrate reagent containing 0.1 M CaCl2 and 2.5 mM ﬂuor-
ogenic substrate Z-Gly-Gly-Arg-AMC.HCl (BACHEM,
Switzerland). Fluorescence is read using a Fluoroskan Ascent
ﬂuorimeter (Thermolab Systems, Helsinki, Finland). The same
batch of reagents was used throughout the study to minimize
interassay variation. PPP samples were tested in duplicate
together with one calibrator (Thrombin Calibrator reagent
ThrombinoscopeTM B.V.) well running in parallel.
Routine coagulation tests
Blood samples were taken in standard Vacutainer (Becton
Dickinson, Plymouth, UK) tubes containing 0.109 M buffered
trisodium citrate and using 23-g butterﬂy needles. Prothrombin
times were performed using PT Fibrinogen HS Plus thrombo-
plastin reagent (Instrumentation Laboratory, Warrington,
UK) with an international sensitivity index (ISI) of 1.15
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according to manufacturers instructions using an ACL TOP
automated coagulometer (Instrumentation Laboratory) as per
routine practice. PT ratios were calculated for each patient
from the geometric mean PT (GMPT) calculated from 23
normal individuals. INRs were calculated using the GMPT
and the manufacturers ISI. FVIII was assayed using a
standard one-stage clotting assay and antithrombin (AT)
activity assays by an in-house chromogenic assay on a ACL
300R. Protein C activity was tested using the HaemosIL
chromogenic protein C assay and free Protein S using the
HaemosIL Free Protein S assay (both bought from Instru-
mentation Laboratory). FII and FV were analyzed by a one-
stage clotting PT-based assay on an ACL 3000 (IL). Tissue
factor pathway inhibitor (TFPI) activity was assayed using the
Actichrome TFPI activity assay (American Diagnostics,
Stamford, USA). Fibrinogen was measured using the recom-
mended Clauss method [17]. Liver function tests and other
analyzes were done as part of routine patient care.
Statistics
All groups of results were tested for normality. Where the
distribution was normal Pearsons correlation test was used. In
the case of non-Gaussian distributions a non-parametric
Spearmans correlation was performed. A P-value of < 0.05
was considered to be statistically signiﬁcant. The normal ranges
were calculated by the mean ± 2 SD if not otherwise speciﬁed.
A hierarchical multiple regression analysis was carried out to
identify independent predictors of the various thrombin
generation parameters. The LT showed a skewed distribution
and was log transformed for normalization purposes in this
model. GraphPad Prism version 4.0.3 (GraphPad Software
Inc., La Jolla, CA, USA) and SPSS version 14.0 (SPSS Inc.,
Chicago, IL, USA) were used for analyzes.
Results
From a total of 73 patients, 47 were men and 26 women, with a
mean age of 53.6 years (range 26–79 years). These were all
non-bleeding patients. Cirrhosis was related to alcohol (ALD)
in 33 patients, hepatitis C virus(HCV) in 15, hepatitis B virus
(HBV) in 1, primary biliary cirrhosis(PBC) or primary
sclerosing cholangitis (PSC) in 10 and cryptogenic cirrhosis in
10 patients. Three patients had HCV and ALD and another
patient had HBV and ALD. The mean MELD value was
12.1 ± 8.8.
The control group consisted of 38 people, 17 males and 21
females. The mean age was 38.4 years (range 24–64 years).
Demographic, clinical and laboratory features of patients are
shown in Table 1a, b.
The INR range was 0.9–5.3 (mean INR 1.7).
Thrombin generation
No correlation was found between the INR and the ETP or
velocity of TG (P ‡ 0.05). There was no difference between the
LT of the normal individuals and the patients (Table 2). The
maximum velocity of thrombin formation was signiﬁcantly
increased in the patients with cirrhosis (difference between the
means )18.71 ± 7.603 nM min)1; 95% CI )33.83 to )3.595;
P = 0.016) (Table 2).
No difference between the mean ETP of the patient group
and the controls was detected (Table 2). Indeed only 8.2% of
patients had an ETP lower than the lower limit of normal (i.e.
682 nM min). The rate of thrombin inhibition was higher in the
controls than in the patients albeit not signiﬁcant (mean 9.97 vs.
8.85 nM min)1; P = 0.27).
Table 1 (a) Patient demographics and routine test results. (b) Coagula-
tion variables
Variable
Result
mean ± SD
Controls and
normal ranges
(a)
Age (years)* 53.6 ± 12.4 38.4 ± 9.8
Gender
Male 47(64.4%) 17 (44.7%)
Female 26 (35.6%) 21 (55.3%)
Etiology of cirrhosis
ALD 33 (45.2%) N/A
HCV 15 (20.6%)
HBV 1 (1.4%)
PBC, PSC 10 (13.7%)
Cryptogenic 10 (13.7%)
HCV and ALD 3 (4.1%)
HBV and ALD 1 (1.4%)
AST (IU L)1)* 75.0 ± 52.1 < 31
ALT (IU L)1)* 58.7 ± 56.9 < 31
ALP (IU L)1)* 166.5 ± 185.6 35–129
WBC* 7200 ± 4000 3500–11000
PLT* 138100 ± 92000 140000–400000
INR* 1.7 ± 0.7 0.9–1.2
Bilirubin (mg dL)1)* 5.0 ± 8.5 < 1.2
Albumin (g L)1)* 34.1 ± 7.1 35–50
Creatinine (mg dL)1)* 1.0 ± 0.5 0.6–1.0
MELD* 12.1 ± 8.8 N/A
Variable
Result
Mean ± SD
Reference ranges
Mean ± SD
(b)
PT (s) 20.1 ± 6.5 13.5 ± 0.9
APTT (s) 40.9 ± 10.4 31.1 ± 2.7
Antithrombin (IU dL)1) 60.5 ± 23.2 98.6 ± 8.6
Protein C (IU dL)1) 46.7 ± 30.9 99.3 ± 19.8
Free protein S (IU dL)1) 93.9 ± 35.1 98.5 ± 15.1
TFPI (U mL)1) 0.99 ± 0.65 1.0 ± 0.20
Fibrinogen (g L)1) 3.3 ± 3.4 2.9 ± 0.4
FII (IU dL)1) 60.2 ± 32.2 101.1 ± 14.0
FV (IU dL)1) 78.4 ± 39.8 92.7 ± 18.1
FVIII (IU dL)1) 184.1 ± 73 113.9 ± 33.0
FXII (IU dL)1) 76.3 ± 36.4 107.8 ± 42.3
*Mean ± SD.
ALD, related to alcohol;HCV, hepatitis C virus;HBV, hepatitis B virus;
PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis;
AST, aspartate aminotransferase; ALT, alanine aminotransferase;
ALP, alkaline phosphatase; WBC, white blood cell count; PLT, platelet
count; INR, international normalized ratio;MELD,model of end-stage
liver disease; PT, prothrombin time; APTT, activated partial
thromboplastin time; TFPI, tissue factor pathway inhibitor.
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As not all patients with cirrhosis had an abnormal INR, we
hypothesized that the above results might be as a result of
skewing owing to patients with normal hemostasis. Hence, we
selected those samples with a high INR (INR > 1.2; n = 49)
and repeated the analyzes. The mean INR was 1.9 (95% CI
1.7–2.1). Again no correlation was detected between the INR
and the various TG parameters. The maximal velocity was
increased in cirrhosis compared with a healthy population
(mean 74.4 ± 34.1 vs. 45.1 ± 25.9 nM min)1, respectively;
P = 0.002). No statistical differences were detected between
controls and this cohort of patients in their ETP and the LT.
We also subdivided the cirrhosis group into those with an
INR between 1.21 and 2.0 (n = 38) and those greater than 2.0
(n = 11) and compared their maximal TG velocity with the
controls to check for different trends depending on the degree
of coagulopathy. Figure 1 shows that the velocity was
increased in the group with INR of 2.0 or less when compared
with the controls (mean 79.7 ± 32.9 vs. 45.1 ± 25.9 nM
min)1, respectively; P £ 0.001). The cohort with the higher
INRs had velocity similar to the normal group (P ‡ 0.05).
The Protac-modified TG assay
Figure 2 shows that upon the addition of Protac, there was a
signiﬁcant difference in the ETP of the patients with cirrhosis
when compared with the controls (mean 1074 ± 461.4 vs.
818 ± 357.9 nM min, respectively; P = 0.004). The ETP
ratio was signiﬁcantly higher in the patients with liver disease
than the normal individuals (mean 0.72 ± 0.26 vs.
0.40 ± 0.16, respectively; P £ 0.0001) (Fig. 3).
Again, we selected those patients with an abnormal INR,
and repeated the analyzes. The ETP ratio was even more
signiﬁcantly increased in the cirrhosis group (mean
0.80 ± 0.21 vs. 0.40 ± 0.16; P £ 0.0001). When patients were
subdivided depending on the degree of coagulopathy, the ETP
ratio was signiﬁcantly increased in those patients with
INR > 1.2 when compared with the controls (see Fig. 4).
Finally, we also checked whether there were any differences
in TG parameters by etiology but no signiﬁcant differences
were found.
Routine coagulation tests
The mean FVIII was raised in the liver cohort (184.1 IU dL)1;
95% CI 165.9–202.3 IU dL)1), AT was reduced (mean
Table 2 Mean (SD) of the individual thrombin generation (TG) param-
eters
TG Parameters Controls Cirrhosis P
LT (s) 4.45 (0.95) 6.31 (5.13) 0.66
Peak (nM) 183 (72.1) 184.2 (72.39) 0.94
Velocity (nM min)1) 45.05 (25.9) 67.95 (34.8) 0.0019
ETP (nM min) 1484 (401) 1331 (414.7) 0.094
LT, lag time; ETP, endogenous thrombin potential.
Controls <1.21 1.21–2.0 >2.0
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Fig. 1. Maximal thrombin generation (TG) velocity depending on the
international normalized ratio (INR) of patients with cirrhosis and com-
paredwith the controls. The velocity was increased in the groupwith INRs
between 1.21 and 2.0, and was similar to the controls in the group with
INR > 2.0 and those patients with cirrhosis but normal INR (group
marked INR < 1.21).
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Fig. 2. The endogenous thrombin potential (ETP) after the addition of
Protac. The ETP in the patients with cirrhosis was increased with a
diﬀerence between the means of 255.4 ± 86.91 nM min (P = 0.004).
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Fig. 3. The endogenous thrombin potential (ETP) ratio between healthy
controls and patients with liver cirrhosis. A signiﬁcant increase in the ETP
ratio is shown in the patient cohort (P £ 0.0001).
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60.5 IU dL)1; 95% CI 54.4–66.6 IU dL)1), FV was normal
(mean 78.4 IU dL)1; 95% CI 68.5–88.3 IU dL)1) as was the
ﬁbrinogen (mean 3.3 g dL)1; 95% CI 2.5–4.2 g dL)1) and
FXII (mean 76.3 IU dL)1; 95% CI 66.6–86.1) (Table 1b). PC
activity was reduced at 46.7 IU dL)1 (95%CI 39–54.4) but free
PS was normal at a mean of 93.9 IU dL)1 as was TFPI activity
(mean 0.99 U mL)1 95% CI 0.83–1.16). The FVIII and
ﬁbrinogen did not correlate with the various TG parameters.
There was a positive correlation between both AT and LT
(Spearmans rho 0.53; P < 0.0001) and a negative correlation
between AT and the ETP ratio (r = )0.53; P < 0.0001). A
negative correlation was also observed between FV and ETP
with Protac and the ETP ratio (r = )0.31, P = 0.014; and
)0.36, P = 0.003, respectively). No correlation was present
between the ETP and TG velocity at 1 pM and the PC or FII.
However, a moderate negative correlation was found between
PC and ETP with Protac and the ETP ratio(r = )0.40,
P = 0.0012 and r = )0.55, P £ 0.0001).
In the multiple regression analysis we studied the effect of all
the coagulation parameters tested on the LT, velocity, peak,
ETP and also the ETP Protac and ETP ratio. Only TFPI
activity was an independent variable on the LT (b = 0.624,
P = 0.002). No individual factor was shown to have an
independent effect on velocity, peak thrombin, ETP, ETP
Protac and ETP ratio.
Discussion
Coagulation in patients with liver disease is complex and varies
in each individual. Not only are there individual pro- and anti-
coagulant and ﬁbrinolytic factors but also ﬁxed cellular
components such as endothelial cells and circulating ones such
as platelets, tissue factor bearing white cells and also red cells.
Flow is also very important, as are genetic predispositions
towards thrombosis or bleeding. It is clear that the PT test not
only assesses a small fraction of all these factors but is only
affected by pro-coagulant factors that decrease in cirrhosis. So
it is not surprising that the PT has never been shown to
correlate with outcomes related to bleeding in patients with
cirrhosis undergoing an invasive procedure.
The present study shows that patients with cirrhosis and a
high INR actually have a hypercoagulable thrombin genera-
tion proﬁle in plasma with an increased maximum velocity of
TG, decreased rate of thrombin inhibition, higher ETP after
the addition of Protac and higher ETP ratios. To our
knowledge, this is the ﬁrst time this has been shown. Splitting
this cohort of patients by different INR groups has allowed us
to identify the most hypercoagulable group which is that with
INRs between 1.21 and 2.0.
We used a low TF concentration and contact inhibition in
our thrombin generation assay to mimic more closely the in
vivo milieu. Looking at the whole thrombin generation
dynamics, we found that the initial stage of thrombin
formation (represented by the LT) is normal in patients with
cirrhosis. Antithrombin levels showed a positive correlation
with the LT indicating another important mechanism in the
balance of hemostasis in similar patients. However, as in
previous studies [18] TFPI was shown to be an independent
variable on the LT. Themaximum velocity index was increased
in cirrhosis when compared with the normal cohort, however,
we could not identify a speciﬁc reason for this. When the PC
anticoagulant pathway was activated with Protac, the ETP
was increased when compared with normal. The resistance
pattern to Protac, as reﬂected by the ETP ratio, showed the
patients to be more resistant to this snake venom and formed
more thrombin. This is the same proﬁle exhibited by patients
with inherited thrombophilia such as PC/PS deﬁciency and FV
Leiden who are well known to be at a greater risk of
thrombosis development [14–16]. This increased Protac
resistance can be explained not only by the reduction in PC
activity levels in cirrhosis but also by the reduction in FV and
the increased FVIII which also lead to activated protein C
resistance. FV not only acts as a cofactor to FXa in the
production of thrombin but when inactivated, it also acts as a
cofactor to activated protein C in the inactivation of FVIIIa.
Hence, it has both procoagulant and anticoagulant properties
in hemostasis. So, overall, as judged by the velocity of TG and
the Protac resistance, the coagulation system in plasma of
patients with cirrhosis is procoagulant. These ﬁndings are in-
keeping with the recent ﬁndings by other groups that patients
with liver disease are not protected against thrombosis despite
the raised INR [19,20], and have an increased thrombotic risk
as compared with age-matched controls [20]. Additionally,
Agarwal et al. [21] recently showed that the coagulopathy of
liver disease did not prevent continuous renal replacement
therapy circuits from clotting.
Controls <1.21 1.21–2.0 >2.0
0.0
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P < 0.001
P < 0.001
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Fig. 4. Endogenous thrombin potential (ETP) ratio depending on the
international normalized ratio (INR) of patients with cirrhosis and com-
pared with the controls. A signiﬁcant diﬀerence was found between the
controls and the patients with INRs greater than 1.2.
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Our study conﬁrms and extends the ﬁndings of Tripodi et al.
[10]. We tried to optimize the TG assay conditions and test a
larger number of patients in order to verify their ﬁndings.
Several groups have shown that when using low TF concen-
trations, contact activation can signiﬁcantly increase thrombin
generation [22,23]. This is especially important when compar-
ing a group with inherently low FXII levels like patients with
cirrhosis to a normal cohort with higher FXII. This spuriously
increases the thrombin generation in the normal controls. This
could explain the differences in the ETP at 1 pM TF between
these two studies. In fact, in our study the mean patient ETP
with CTI was equivalent to normal whereas using the same TF
concentration, Tripodi et al. found that the mean ETP was
lower in the cirrhosis group. One could argue that another
possible explanation is the difference between the trigger
reagents used in the two studies. Albeit both at 1 pM, the TF in
our study was Innovin whereas in the other study Recom-
biplastin with a lower phospholipid concentration (4 vs.
0.5 lmol L)1) was used. However, in both studies the patient
group was compared with a normal control group studied in
exactly the same way and hence this does not readily explain
the differences outlined.
The use of the Protac in our study instead of soluble
recombinant thrombomodulin (rTM) to activate PC has
already been shown to be suitable in other patient cohorts
[14–16]. The two reagents activate endogenous PC and in both
cases, an empirical concentration of activator is used. Also,
TM is a transmembrane protein cofactor expressed on
endothelial cells. It is as yet not possible to emulate this
environment using the CAT. However, our results are very
similar to those using soluble rTM and we show that thrombin
generation is not only normal but increased in patients with
cirrhosis when the protein C pathway is activated with Protac
[10]. We feel that it is also important to note the increased
resistance pattern to Protac that we demonstrated in patients
with liver disease, as this is similar to that seen in patients with
defects in their PC pathway leading to a prothrombotic state.
Finally, we have demonstrated that the majority of patients
with INRs greater than 1.2 are resistant to Protac but those
with INRs between 1.21 and 2.0 also demonstrate increased
thrombin generation velocities making them possibly more
hypercoagulable. Further studies are required to look specif-
ically at a larger patient group with INRs greater than 2.5 in
order to ascertain whether this phenomenon is largely conﬁned
to those patients with mild to moderate coagulopathy.
Some limitations in our study need to be addressed. First, we
did not use platelet-rich plasma in our thrombin generation
tests. Cirrhosis usually leads to thrombocytopenia which
results in lower thrombin generation [24]. However, the main
aim of our study was to compare the coagulopathy indicated
by the PT which is a PPP-based test with thrombin generation.
In order to compare like-with-like, we used PPP in the TG
assays as well. This means that in clinical practice, these
patients might still require platelet support, depending on their
platelet count. Another limitation is the age and gender
differences between the patients and the controls. Age has been
shown to correlate positively with TG [25,26]. Our control
group was slightly younger than the patient group and this
might have inﬂuenced our results. However, we do not believe
that this was a major confounder as both groups were adults
and the mean age difference was only 15.2 years. Studies have
shown that the main age-related differences in TG are in
newborns/childhood vs. adults. No one has actually looked at
particular differences per decade and these would be expected
to be small as judged by the correlation coefﬁcients of these
variables in these studies [25]. Also, if age was a major
confounder, one would have expected all patients groups to
have increased velocity of TG and not just the ones with INR
1.21–2.0. With regards to gender, thrombin generation has
been shown to be higher in females than in males and after the
addition of Protac or rTM females show more activated
protein C resistance [14,25]. Since our control group included
more females than males whereas the patient group had more
males than females, it would have been expected that both the
velocity and the ETP ratio would have been lower in the patient
group and not higher.
In conclusion, we demonstrated that overall, as judged by
the CAT, the coagulation balance in patients with cirrhosis-
induced coagulopathy favours thrombosis. This not only
provides a pathophysiological mechanism underlying the
increased risk of thromboembolism in epidemiological studies
[20], but also adds more evidence against the long respected
dogma of autoanticoagulation in similar patients. It also
supports the view that the PT/INR test should not be used to
assess bleeding risk and that in the majority of cases,
prophylactic transfusion of clotting factors, such as fresh
frozen plasma, is not warranted and could be hazardous by
increasing the tendency to thrombosis and delaying some
clinically important diagnostic and therapeutic procedures. The
data also suggests that a prolonged PT per se should not deter
physicians from considering appropriate chemical thrombo-
prophylaxis when similar patients are hospitalized. Our results
justify the need for new studies to generate new guidelines for
the prophylactic and therapeutic use of blood products in
cirrhosis. Finally, measuring thrombin generation could be the
way forward in assessing hemostasis and to guide the use of
hemostatic agents in similar patients and also merits evaluation
using outcome studies. It would be interesting to see whether
the newly devised INR (liver) system [27,28] could also result in
a better test to assess bleeding risk in people with liver disease.
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